The Uromigos strives to provide balanced, scientific content related to care of patients with GU malignancies. Click the link below to listen to our podcasts.
Worldwide
Joined February 2017
- Tweets2.7K
- Following482
- Followers7.8K
- Likes889
A new Phase 3 study puts triplet therapy in metastatic kidney cancer in the spotlight.
Live from #ESMO2026, Dr. Martin Voss takes over hosting duties to interview Brian and Tom about new Phase 3 data exploring triplet therapy in metastatic clear cell renal cell carcinoma (ccRCC).
🎙️ Episode 528 of The Uromigos Podcast is now live: bit.ly/4zbg4n6
#Uromigos #KidneyCancer #GUOncology
What could new Phase 3 data mean for high-risk prostate cancer?
From #ESMO2026, Dr. Chris Sweeney joins Brian and Tom to discuss new findings from an ANZUP trial, adding to the growing body of Phase 3 evidence in the high-risk prostate cancer setting.
🎙️ Episode 527 of The Uromigos Podcast is now live: bit.ly/4yBisT3
#Uromigos #ProstateCancer #GUOncology
Uromigos retweeted
Excellent presentation by @tompowles1! VOLGA: perioperative durvalumab + 3 cycles of neoadjuvant EV improved EFS (HR 0.51) and OS (HR 0.58) vs cystectomy ± adjuvant therapy in cisplatin-ineligible/declining MIBC. ADCs moving earlier! #ESMO26 @oncoalert @myESMO
Uromigos retweeted
#ESMO26 Phase II sac-TMT + pembro in 1L cisplatin-ineligible advanced UC (n=40, 60% UTUC)
Median PFS 11.2 mo, OS NR and G3/4 TRAEs 63%
Promising results although its place in the EVP era remains to be defined. Worth exploring this combination in other settings
@OncoAlert
Uromigos retweeted
SAC-TMT + pembro shows 68% response rates in metastastic bladder cancer #ESMO2026 . Trofuse-55 explores this combination in bladder sparing approaches in a randomized phase 3. The triplet with EVP seems a justified research randomised question. Triplet data from yesterday showed 81% RRs. @OncoAlert
Uromigos retweeted
Kudos @tompowles1 on a fantastic #VOLGA presidential @ #ESMO26 👏
Less is More!
• Cis-inelig MIBC, 25% were cis refusers
• D+EV x3 → RC → adj D x9 (NO adj EV)
• EFS HR 0.51
• OS HR 0.58
• pCR 45 vs 10%
• G3-4 TRAE 30%,
• neuropathy only 18%
• imAEs 33% (G3-4 11%)
• GHS/QoL maintained post-RC
• Treme ↑tox (G3-4 42%, 5 deaths), NO OS gain.
My take: it's not just about chasing bigger numbers. Tox matters too, especially when OS is achieved. Need to discuss the pros and cons with patients.
Less PN and skin tox, and fewer G3+ immune AEs than more cycles and that's a win for patients ! 🙌
@Uromigos @OncoAlert @brian_rini @LosUromigos @drenriquegrande
The #ESMO26 Presidential Symposium is about to begin! 🔥
Super excited to hear the highly anticipated results of the VOLGA trial, presented by the the only and only @tompowles1!
@myESMO
@apolo_andrea @Uromigos @brian_rini @OncoAlert @LosUromigos @uromigosjapan @MichvdHeijden
Uromigos retweeted
VOLGA also explored short periods of EV with duvalumab and tremelimumab in muscle invasive bladder cancer #ESMO26 @NEJM. Results showed EVDT improved EFS vs cystectomy (HR 0.61). Significant OS was not reached at this interim (HR 0.77 -ongoing analysis). EVDT = 10% higher rates of G3/4 toxicity and less EV delivery than the EV durvalumab arm. More is not always better. It appears the addition of treme partly compromised delivery of EV, which likely accounts for the more modest results compared to the doublet @OncoAlert
How are new data reshaping the muscle-invasive bladder cancer landscape?
Live from #ESMO2026, Dr. Michiel van der Heijden joins Brian and Tom following his ESMO discussion and Tom's presentation to unpack the latest findings in MIBC and what they could mean for clinical practice.
🎙️ Episode 526 of The Uromigos Podcast is now live: bit.ly/4kgelIh
#Uromigos #BladderCancer #GUOncology
What can longer follow-up tell us about treatment in metastatic hormone-sensitive prostate cancer?
Live from #ESMO2026, Dr. Karim Fizazi joins Brian and Tom to discuss two presentations featuring long-term follow-up data in mHSPC and what these findings could mean for clinical practice.
🎙️ Episode 525 of The Uromigos Podcast is now live: bit.ly/4icoCmd
#Uromigos #ProstateCancer #GUOncology
Could a new mechanism change how we target prostate cancer?
Live from #ESMO2026, Dr. Ben Garmezy joins Brian and Tom to discuss Phase 1 data on RIPTAC, a novel approach that uses the androgen receptor (AR) to target BRD4 and disrupt cancer cell transcription.
🎙️ Episode 524 of The Uromigos Podcast is now live: bit.ly/4z6zWaG
#Uromigos #ProstateCancer #GUOncology
Uromigos retweeted
#ESMO26 KEYNOTE-B15 HRQoL results further support perioperative EVP in MIBC
No clinically meaningful differences in HRQoL despite improved EFS and OS. The greatest deterioration occurred in both arms after surgery (sexual dysfunction)
Congrats @Uro_Oncologist!
@OncoAlert
Uromigos retweeted
Proud to share our exploratory analysis from DISCUS at #ESMO26 @BartsECMC
- 34% of patients never reached avelumab
- 3C vs 6C increased transition (74% vs 57%), with fewer PD/death events
- QoL remained stable on ICI and baseline PS was the only differentiating factor @OncoAlert
Uromigos retweeted
Podcast here:
podcasts.apple.com/us/podcas…
ctDNA analysis from the EVP vs chemotherapy muscle invasive bladder cancer trial (B15/EV304) shows ctDNA is strongly prognostic at all time points for both arms. EVP has higher clearance rates across time points, underlining its ⬆️ activity. Results for the control arm are strikingly similar to the ctDNA results in the chemo control arm in the NIAGARA trial. This consistency underlines the utility of ctDNA from a prognostic perspective.#ESMO26 @OncoAlert
Uromigos retweeted
#ESMO26
Adding perioperative pembro to Gem/Cis did not significantly improve EFS in cis-eligible MIBC (HR 0.88) in KN866.
Higher pCR rates (although not formally tested) were seen in the pembro arm.
More info in the concomitant publication in @Annals_Oncology
@OncoAlert
Uromigos retweeted
It hard to explain why 1 trial with gem/cis +/-PD(L)1 (NIAGARA) is +ve for EFS/OS and 2 very similar trials (presented today) are negative in MIBC. Potentially NIAGARA has the highest risk population, not all respond to IO and the maintenance phase the most effect- but the OS of gem/cis pembro HR of 1 is concerning. This reflects what we saw in metastatic disease with contradictory results for the big combination trials. Overall EVP looks better and more consistent #ESMO26 @myESMO @Annals_Oncology @OncoAlert
Uromigos retweeted
ABBV-969 dual-targeting ADC #ESMO26
MOA = PSMA/STEAP1— TOPO1
Deep responses in metastatic castration-resistant prostate cancer
Surely this one can beat Docetaxel?
What can circulating tumor DNA reveal about treatment response?
The KEYNOTE-905 conversation continues at #ESMO2026.
Following his presentation, Jon Chatzkel joined Brian and Tom to explore ctDNA kinetics from the trial and what these findings may tell us about the biological response to neoadjuvant treatment in muscle-invasive bladder cancer.
🎙️ Episode 523 of The Uromigos Podcast is now live: apple.co/47AYGMk
#Uromigos #BladderCancer #ctDNA #GUOncology
What can KEYNOTE-905 tell us about treatment before surgery?
Following his presentation at #ESMO2026, Dr. Anders Ullén joins Brian and Tom to discuss the KEYNOTE-905 trial in cisplatin-ineligible muscle-invasive bladder cancer.
The conversation examines neoadjuvant pembrolizumab and enfortumab vedotin plus pembrolizumab (EVP) versus immediate cystectomy, and the questions these approaches raise.
🎙️ Episode 522 of The Uromigos Podcast is now live: apple.co/4iCMOiY
#ESMO2026 #Uromigos #BladderCancer #GUOncology
What happens when clinical trial results don't align?
Two Phase 3 trials presented at #ESMO2026 did not demonstrate a benefit from adding immunotherapy to chemotherapy MIBC.
Dr. Rob Jones joins Brian and Tom to unpack the findings, explore how they fit alongside the NIAGARA data, and discuss the implications for neoadjuvant and adjuvant treatment strategies.
🎙️ Episode 521 of The Uromigos Podcast is now live: bit.ly/4z7YGQ5
#Uromigos #BladderCancer #GUOncology
